SCHEMBL20745836

SCHEMBL20745836

CCOC(=O)c1cc2sc(SC)nc2n1C1CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
GRK6 P43250 1/20 0.40
TSHR P16473 3/20 0.37
USP2 O75604 1/20 0.37
PDE5A O76074 1/20 0.37
OPRM1 P35372 3/20 0.36
OPRK1 P41145 3/20 0.36
OGFRL1 Q5TC84 3/20 0.36
ALDH1A1 P00352 2/20 0.35
HSD17B10 Q99714 2/20 0.34
POLB P06746 1/20 0.34
OPRD1 P41143 2/20 0.34
KDM4E B2RXH2 1/20 0.34
DHODH Q02127 1/20 0.34
PIK3CA P42336 1/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
NPC1 O15118 1/20 0.34
CRHBP P24387 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20745549 0.82 LMNA (0.48) LMNATSHRALDH1A1HSD17B10POLB
SCHEMBL20745626 0.81 LMNA (0.47) LMNATSHRUSP2ALDH1A1HSD17B10
SCHEMBL20745577 0.76 ALDH1A1 (0.46) LMNATSHRUSP2ALDH1A1HSD17B10
SCHEMBL20745714 0.73 LMNA (0.42) LMNAGRK6TSHRUSP2OPRM1
SCHEMBL25091255 0.71 MEN1 (0.48) ALDH1A1POLB
SCHEMBL25091286 0.70 MEN1 (0.47) OPRM1OPRK1OGFRL1ALDH1A1POLB
SCHEMBL7478527 0.69 GRK6 (0.41) LMNAGRK6USP2ALDH1A1KDM4E
SCHEMBL31302532 0.68 LMNA (0.51) LMNAALDH1A1HSD17B10KDM4EGAA
SCHEMBL12490981 0.67 NOD2 (0.55) GRK6OPRM1OPRK1OGFRL1ALDH1A1
SCHEMBL20745428 0.66 TSHR (0.44) TSHRALDH1A1HSD17B10POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11957680-B2 Pyruvate kinase activators for use in treating blood disorders AGIOS PHARMACEUTICALS, INC. (US) 2024-04-16 US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
EP-3668881-B1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS INC (US) 2023-10-04 EP disclosed
EP-3668881-B1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS INC (US) 2023-10-04 EP disclosed
CN-111032046-B Pyruvate kinase modulators and uses thereof 安吉奥斯医药品有限公司 2023-09-26 CN disclosed
EP-3668512-B1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS INC (US) 2023-02-15 EP disclosed
US-20220395503-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2022-12-15 US disclosed
US-20220395503-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2022-12-15 US disclosed
US-20210130371-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2021-05-06 US disclosed
US-20210130371-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2021-05-06 US disclosed
US-20200206225-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS, INC. (US) 2020-07-02 US disclosed
US-20200206225-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS, INC. (US) 2020-07-02 US disclosed
EP-3668881-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS Agios Pharmaceuticals, Inc. (US) 2020-06-24 EP disclosed
EP-3668512-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF Agios Pharmaceuticals, Inc. (US) 2020-06-24 EP disclosed
CN-111032046-A Pyruvate kinase modulators and uses thereof 安吉奥斯医药品有限公司 2020-04-17 CN disclosed
WO-2019035863-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. (US) 2019-02-21 WO disclosed
WO-2019035865-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS INC. (US) 2019-02-21 WO disclosed
WO-2019035863-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. (US) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11872225-B2 Pyruvate kinase modulators and use thereof PDK1, PDK2, PDK4 LMNA 1466/4885GRK6 459/4885TSHR 679/4885
US-20210130371-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PDK1, PDK2, PDK3 LMNA 1137/4885GRK6 689/4885TSHR 1925/4885
US-20200206225-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF PDK1, PDK2, PDK4 LMNA 1466/4885GRK6 459/4885TSHR 679/4885
US-20220395503-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PDK1, PDK2, PDK3 LMNA 1137/4885GRK6 689/4885TSHR 1925/4885
US-11957680-B2 Pyruvate kinase activators for use in treating blood disorders PDK1, PDK2, PDK3 LMNA 1137/4885GRK6 689/4885TSHR 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.